BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality - 2Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- 3Vote In favor of Your Favored Kind Of Cheddar
- 4The Most Compelling Books of the 10 years
- 5The most effective method to Make a Dazzling Site in 5 Basic Advances
- Upgrading the Healthy benefit of Your Local Vegetables
- Exemplary Fragrances: A Manual for Notorious Scents
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- German police 'cleared path for fascists with batons,' protesters say
- Truly amazing Palaces: Which Is Your Number one?
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
